Sylvain Choquet

12.3k total citations · 1 hit paper
174 papers, 3.3k citations indexed

About

Sylvain Choquet is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Sylvain Choquet has authored 174 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Pathology and Forensic Medicine, 81 papers in Genetics and 79 papers in Oncology. Recurrent topics in Sylvain Choquet's work include Lymphoma Diagnosis and Treatment (80 papers), CNS Lymphoma Diagnosis and Treatment (61 papers) and Chronic Lymphocytic Leukemia Research (46 papers). Sylvain Choquet is often cited by papers focused on Lymphoma Diagnosis and Treatment (80 papers), CNS Lymphoma Diagnosis and Treatment (61 papers) and Chronic Lymphocytic Leukemia Research (46 papers). Sylvain Choquet collaborates with scholars based in France, United States and Germany. Sylvain Choquet's co-authors include Véronique Leblond, Khê Hoang‐Xuan, Carole Soussain, Caroline Houillier, Ralf Ulrich Trappe, V. Leblond, Hanno Riess, Stephan Oertel, Vincent Lévy and Martine Raphaël and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sylvain Choquet

154 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

T cell malignancies after CAR T cell therapy in the DESCAR-T registry

2025 23 citations Sylvain Choquet, Catherine Thiéblemont et al. profile →

Peers

Sylvain Choquet

PFM

ONCOL

NEURO

GENET

EPIDE

Kosei Matsue Japan

Thomas Klingebiel Germany

Christiane Copie‐Bergman France

Marie‐Hélène Delfau‐Larue France

V. Leblond France

Kirit M. Ardeshna United Kingdom

Claudio Agostinelli Italy

Carl D. Winberg United States

Françoise Berger France

Naoko Asano Japan

Kosei Matsue Japan

Sylvain Choquet

1.1k ×0.6

PFM

1.1k ×0.6

ONCOL

733 ×0.6

NEURO

736 ×0.7

GENET

453 ×1.0

EPIDE

Citations per year, relative to Sylvain Choquet Sylvain Choquet (= 1×) peers Kosei Matsue

Countries citing papers authored by Sylvain Choquet

Since Specialization

Citations

This map shows the geographic impact of Sylvain Choquet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvain Choquet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvain Choquet more than expected).

Fields of papers citing papers by Sylvain Choquet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvain Choquet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvain Choquet. The network helps show where Sylvain Choquet may publish in the future.

Co-authorship network of co-authors of Sylvain Choquet

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvain Choquet. A scholar is included among the top collaborators of Sylvain Choquet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvain Choquet. Sylvain Choquet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghobadi, Armin, Robert A. Baiocchi, Sridhar Chaganti, et al.. (2025). Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein–Barr Virus–Driven Posttransplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy. Transplantation and Cellular Therapy. 31(2). S506–S507.

Pérol, Louis, Carole Soussain, Khê Hoang‐Xuan, et al.. (2025). ICE polychemotherapy is an efficient salvage treatment in primary central nervous system lymphoma: an LOC network study. Blood Advances. 9(8). 1801–1804. 1 indexed citations

Samara, Jumana, Marine Baron, Christophe Parizot, et al.. (2025). CD8 and CD4 CAR-T cells are associated with outcome and toxicity of tisagenlecleucel in central nervous system lymphoma. Cytotherapy. 27(8). 933–937. 1 indexed citations

Cabannes‐Hamy, Aurélie, Floriane Jochum, Kévin Bihan, et al.. (2025). BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase. Clinical Pharmacology & Therapeutics. 118(3). 705–714.

Hernández-Verdín, Isaias, Karima Mokhtari, Élise Sourdeau, et al.. (2025). Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: An ancillary study from the BLOCAGE trial. Neuro-Oncology. 27(8). 2090–2104.

Choquet, Sylvain, Bertrand Mathon, Magali Le Garff‐Tavernier, et al.. (2025). Mild Metabolism Increase on Posttreatment 18F-FDG PET may Indicate Recurrence of Primary CNS Lymphoma. Clinical Nuclear Medicine. 50(11). 1060–1061.

Rozenblum, Laura, Caroline Houillier, Amandine Baptiste, et al.. (2024). Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: An LOC network prospective multicentric study. Neuro-Oncology. 26(7). 1292–1301. 2 indexed citations

Houillier, Caroline & Sylvain Choquet. (2024). CAR T-cell Therapy for Central Nervous System Lymphoma. Current Oncology Reports. 26(11). 1521–1529. 2 indexed citations

Armand, Marine, Élise Sourdeau, Karima Mokhtari, et al.. (2023). Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell‐free DNA improves diagnosis of primary CNS lymphoma. British Journal of Haematology. 201(6). 1088–1096. 12 indexed citations

10.

Weiss, Nicolas, Sylvain Choquet, Cristina Birzu, et al.. (2023). JS03.6.A NEUROTOXICITY IN PATIENTS WITH CNS LYMPHOMAS TREATED WITH CAR T CELL THERAPY. A LOC NETWORK STUDY. Neuro-Oncology. 25(Supplement_2). ii7–ii8. 1 indexed citations

11.

Baptiste, Amandine, Lisa Belin, Pascale Ghillani‐Dalbin, et al.. (2022). Immunochemotherapy versus rituximab in anti‐myelin‐associated glycoprotein neuropathy: A report of 64 patients. British Journal of Haematology. 198(2). 298–306. 4 indexed citations

12.

Gougis, Paul, Arthur Géraud, Marc Hilmi, et al.. (2022). Cytochrome P-450-mediated herb and food–drug interactions can be identified in cancer patients through patient self-reporting with a tablet application: results of a prospective observational study. ESMO Open. 7(6). 100650–100650. 1 indexed citations

13.

Armand, Marine, et al.. (2022). Prevalence of IGLV3-21R110 among familial CLL: a retrospective study of 45 cases. Blood Advances. 6(12). 3632–3635. 1 indexed citations

14.

Prockop, Susan E., Kris M. Mahadeo, Amer Beitinjaneh, et al.. (2021). Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Blood. 138(Supplement 1). 301–301. 8 indexed citations

15.

Sabbah, Mohamad, et al.. (2021). Successful treatment of an EBV‐positive HIV‐associated polymorphic B‐cell lymphoproliferative disorder by rituximab monotherapy. SHILAP Revista de lepidopterología. 2(3). 562–564. 2 indexed citations

16.

Xochelli, Aliki, Claude Lesty, Nathalie Cassoux, et al.. (2020). Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire. Blood Advances. 4(7). 1357–1366. 25 indexed citations

17.

Costopoulos, Myrto, Rathana Kim, Sylvain Choquet, et al.. (2017). Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination. Seminars in Hematology. 55(4). 179–181. 5 indexed citations

18.

Woillard, Jean‐Baptiste, Jean Debord, Isabelle Benz‐de Bretagne, et al.. (2017). A Time-Dependent Model Describes Methotrexate Elimination and Supports Dynamic Modification of MRP2/ABCC2 Activity. Therapeutic Drug Monitoring. 39(2). 145–156. 12 indexed citations

19.

Trappe, Ralf Ulrich, Sylvain Choquet, Stephan Oertel, et al.. (2007). Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II study. Queensland's institutional digital repository (The University of Queensland). 1 indexed citations

20.

Trappe, Ralf Ulrich, Sylvain Choquet, Petra Reinke, et al.. (2007). Salvage Therapy for Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) With a Second Progression of PTLD After Upfront Chemotherapy: The Role of Single-Agent Rituximab. Transplantation. 84(12). 1708–1712. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact